REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the management of HIV infection and AIDS. Important trends are identified and sales’ forecasts by product categories and major country markets are provided through 2016; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the HIV/AIDS market. The wider economic environment is also taken into account.
REASONS FOR DOING THE STUDY
HIV/AIDS is one of the most catastrophic threats to human health throughout the world. Advanced treatment options and improved methods of diagnosis have helped to moderate the growth of the epidemic and this has presented opportunities for companies prepared to engage actively in this field. However, the management of HIV/AIDS is still, in many respects, an unfulfilled market and there is an ongoing urgent need for promising new research directions as well as optimal exploitation of the treatment and diagnostic options already developed. In this dynamic and continually evolving marketplace, there is a need for an up-to-date, comprehensive appraisal covering both strategic and tactical options confronting the pharmaceutical industry.
SCOPE OF REPORT
This report summarizes knowledge of HIV/AIDS and discusses the present status and evolution of the global AIDS epidemic, with analyses by selected major national markets. Latest treatment and diagnostic options and practices are described and their cost implications clarified, especially in the context of treatment affordability in countries of widely varying economic status. The emergence of a considerable generic medicine component in the marketplace, alongside the presence of original branded medicines, is discussed; profiles of both originator companies and generic suppliers are included and the role of governmental and charitable agencies explained. The current market for AIDS therapies is analyzed with breakdowns by major country and 5-year forecasts. Finally, major ongoing research is summarized and promising directions identified.
MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected at 2011 dollar value without attempting to predict the effect of inflation/deflation.
National market analyses and forecasts are provided for seven economically advanced countries and for five countries classified as of low to medium economic advancement.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. Primary research included interviews with leading individuals in pharmaceutical companies and industry associations. Primary sources of published data included company annual reports, SEC filings, and government and industry publications. Secondary sources consisted of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts were pooled from a range of sources and critically assessed by BCC.
INTENDED AUDIENCE
This report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.
INFORMATION SOURCES
Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant trade associations such as Pharmaceutical Journal and AIDS Research and Therapy.
ANALYST CREDENTIALS
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the HIV/AIDS marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at
www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place
- direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers.
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The authors assume no responsibility for any loss or damage that might result from reliance on the reported information or its use.
